Case 48Semiconductor Roadmap And Capital ExecutionFailure

Intel compute-roadmap and capital-economics failure

Intel Corporation · 2015–2025

For a simulated long-only public-equity committee using only evidence public by May 2, 2016, should any new Intel exposure be initiated or added, and what technical, roadmap, segment, manufacturing, funding, and valuation gates should govern human re-underwriting of any existing holding?

Start with Part A Read outcome & teaching note

At the decision boundary

Intel compute-roadmap, segment-economics, and funding decision

Decision time: May 3, 2016
Knowledge cutoff: May 2, 2016
Recommended path: Initiate no new exposure and add no capital on the selected record. DCG growth, manufacturing scale, and positive cash generation do not resolve 10nm validation, product cadence, CCG economics, manufacturing returns, acquisition-funded leverage, or valuation. Route any existing holding to the authorized human committee for governed re-underwriting; this packet neither sizes nor executes a trade.
Confidence: Moderate

What happened

No actual investor action is observed. Frozen Part A recorded a simulated defer-and-re-underwrite recommendation: initiate no new exposure, add no capital, and route any existing holding to an authorized human committee. The selected record contains no actual holding, mandate, order, execution, or evidence that Intel or a real investment committee used Part A's six gates.

Part A's defer-and-re-underwrite recommendation was a prudent risk-control response to missing technical, roadmap, segment, manufacturing, funding, and valuation evidence. The later 7nm delay, FY2024 stress, Foundry losses, low external revenue relative to total Foundry segment revenue, and 14A customer-volume contingency are consistent with the negative branch that Part A protected against. Profitable Intel Products, the reported 18A milestone, and the improved raw reported FY2025 consolidated endpoint show why the six gates should remain separate and why a categorical short, terminal-failure call, or autonomous trade would have exceeded the evidence. Later outcomes do not prove a security return, an actual committee action, or that the simulated recommendation was profit-maximizing.

Case inventory

What is inside

14source records

16financial tables

38material claims

3candidate rules

Transfer with care

Rule hypotheses from this case

All rule hypotheses →

Candidatemoderate confidence

rule.require-semiconductor-roadmap-evidence-chain

Defer new capital and route the case to an authorized human underwriting committee; require a versioned planned-versus-actual evidence chain across technical validation, product timing, qualification, customer deployment, segment economics, and funding before any human-approved change in exposure.

A named node, launch, or high-volume label can show activity without proving competitive yield, reliable qualification, customer adoption, or adequate economics, while process misses can propagate into product timing and fixed-cost absorption.

Candidatehigh confidence

rule.separate-products-foundry-and-intersegment-economics

Require the human underwriting committee to underwrite product economics, manufacturing economics, external foundry economics, intersegment pricing and eliminations as separate ledgers; abstain from an all-company quality or failure conclusion until the bridges are reconciled.

Internal transfer revenue can demonstrate production activity without external customer validation, and profitable products can coexist with manufacturing losses that consolidated results or a single segment narrative obscures.

Candidatehigh confidence

rule.reconcile-semiconductor-capital-and-funding-perimeters

Require an authorized human committee to approve one obligation-adjusted sources-and-uses schedule that preserves every GAAP, supplemental, ownership, incentive, vendor-financing, partner, equity and non-GAAP perimeter; abstain from capital-return, valuation, and exposure changes until the schedule and downside funding gates clear.

Cash classification, payment timing, noncash acquisition, shared ownership, incentives, dilution and asset sales can make gross investment, net investment, reported cash generation and shareholder funding appear interchangeable when they are not.

Read against

A contrasting case sharpens the boundary.

Semiconductor Roadmap And Capital ExecutionAMD compute-roadmap and funding turnaroundFor a simulated long-only public-equity committee using only evidence public by May 2, 2016, should it initiate or add AMD exposure, maintain an existing holding without new gates, defer and re-underwrite, or route a possible reduction to an authorized human, and what six evidence gates must govern any later capital action?